Portland, OR-Researchers in the Casey Eye Institute at Oregon Health & Science University (OHSU) began participation in February in a gene therapy trial for patients with age-related macular degeneration (AMD).
Around the Helix: Cell and Gene Therapy Company Updates – September 18, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Ongoing Research Seeks to Address Challenges With Muscular Dystrophy Gene Therapy
Jeffrey Chamberlain, PhD, McCaw Endowed Chair of Muscular Dystrophy at University of Washington, highlighted studies presented at MDA's 2024 conference.
Vironexis Biotherapeutics’ AAV Vector-Based Immunotherapy VNX-101 Cleared for US Trial in Acute Lymphoblastic Leukemia
VNX-101 is intended to transduce cells of the liver, causing them to express a transgene coding for a bispecific T-cell engager.
Data Roundup: August 2024 Features Updates in CAR-T, mRNA Therapy, and Gamma Delta T-cell Therapy for Various Cancers
Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.
BridgeBio Pharma Drops Development of Congenital Adrenal Hyperplasia Gene Therapy BBP-631
The company made the decision to axe the program in light of newly reported topline results from the clinical study.
From Grad Work to Gene Therapy Approval
Jeffrey Chamberlain, PhD, McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed his research career with muscular dystrophies.